• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

“We need to ensure that results of R&D are affordable and available to patients”

Home > Viewpoints

“We need to ensure that results of R&D are affordable and available to patients”

15 Feb 2017
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Graeme Bilbe

Viewpoint by

Graeme Bilbe, Research & Development Director, DNDi

What would you say were the three main achievements in DNDi’s R&D portfolio in 2016?

The first thing that comes to mind is sleeping sickness. We’ve reached an important milestone for DNDi with fexinidazole as it is our first new chemical entity (NCE) to get through Phase II/III clinical trials successfully. Not only that, but we only lost two out of a total of 390 patients to follow up. This is truly an incredible result in the real-life conditions of running clinical trials in the DRC, so kudos to the clinical teams. And behind fexinidazole, we have another oral drug, SCYX-7158, in Phase II/III trials, so there is lots of promise.

Second, I’d say the advances in our leishmaniasis pipeline. We now have two pre-clinical candidates, and two other series in advanced lead optimization, plus our partners have signaled up to an additional four compounds close to pre-clinical candidate development. Together with our partners, we have NCEs representing six new classes of potential drug with unprecedented efficacy against both visceral and cutaneous leishmaniasis in animal models. So overall, the pipeline is looking very healthy and could transform the treatment landscape for leishmaniasis.

And in three, I’d pick the great strides made by our team working on hepatitis C. In less than a year, we’ve gone from signing a Memorandum of Understanding with the Egyptian drug manufacturer Pharco Pharmaceuticals, building a great collaboration with Malaysian and Thai governments, and now we have about 190 patients enrolled in our Phase II/III trial.

Have our R&D strategies evolved much since DNDi was created?

From the start, we took a three-pronged strategy: short- medium- and long-term. Short-term means improving access to existing medicines by completing registration and extending the geographical reach of existing treatments. In the medium-term, the focus was on therapeutic switching, combining and reformulating existing treatments to improve them so that they are better adapted to field conditions and patient needs. ASAQ for malaria, NECT for sleeping sickness, and SSG&PM for visceral leishmaniasis are some of the results of this short- and medium-term strategy.

For some of these, the treatments we developed are still be suboptimal, in that R&D needs still remain acute. But without question they have saved neglected patients’ lives. The impact of NECT for example is pretty telling: the number of HAT cases has decreased from hundreds of thousands to tens of thousands, and there are now only 3,000 left in those areas that we have been able to access.

For other disease areas, progress has been slower. Our work on paediatric benznidazole has taught us a huge amount about Chagas disease. We have trail-blazed the use of PCR as a readout for parasitaemia and have hope for a future proof of cure. Using PCR, we discovered that benznidazole is quite effective, so we are now working on alternative regimens and combinations to increase its tolerability.

As for the long-term: DNDi’s strategy is to invest in drug discovery to produce new fit-for-purpose treatments with improved efficacy and tolerability. These efforts are bearing fruit – we currently have 15 NCEs in our pipeline for all kinetoplastid diseases, mycetoma and hepatitis C.

Looking ahead, what future challenges do you foresee for DNDi within the broader R&D landscape?

The main challenge for DNDi’s R&D teams will always be to deliver new treatments. R&D for infectious diseases is subject to high attrition: we estimate that for every 1,000 hits only one will become a registered drug.  Our way of mitigating that has been to increase substantially our number of clinical research projects and develop an integrated strategy for drug discovery, including risk management strategies.

But we have enormous faith in the DNDi model. So much so that a few years ago we decided to evaluate regularly any new potential disease to add to the DNDi portfolio and determine whether DNDi can have an impact and should enter the field. We’re expecting this to result in investment in new disease areas or fields of research and hence an increased number of partners – one immediate example is antimicrobial resistance, where we established the Global Antibiotic Research and Development Partnership (GARDP) in collaboration with WHO last year.

Another challenge will be how to continue to raise awareness for diseases that remain more than neglected, such as mycetoma, which are ignored in the shadow of deadly outbreaks of viral diseases like Ebola. And access to treatments will definitely remain a priority action. We still need governments to acknowledge that some diseases such as Chagas disease are a public health issue in their countries, and for all stakeholders to take responsibility and provide support to ensure patients aren’t neglected. Securing access to affordable hepatitis C regimens will also be a critical challenge.

It’s important to remember DNDi was only ever meant to be part of the solution for neglected patients. We’ve advocated for governments to create a framework for all R&D actors to work within, that is sustainable, focused on public health priorities and patients’ needs, and ensures that the results of R&D are affordable and available. And while there’s no shortage of expert reports that recommend that a framework along these lines be created, we’re not yet seeing enough government action that will address all areas of public health importance.  Going forward, that is the challenge at its most fundamental.

Graeme Bilbe, Research & Development Director, DNDi

Policy advocacy

Read, watch, share

Loading...
Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

Healthcare workers looking into microscopes
Press releases
30 Nov 2022

Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

Journalists talking with healthcare workers
News
23 Nov 2022

DNDi media workshops – bringing together reporters and researchers to cover neglected disease research

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo